Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Study Compares Survival Outcomes Using Different Cancer Staging Methods

By HospiMedica International staff writers
Posted on 05 Oct 2016
Researchers in the Netherlands have compared five-year survival rates for mediastinal nodal lung cancer staging, after treatment with endosonography or mediastinoscopy.

The results of the study were published in the September 13, 2016, issue of the journal JAMA. More...
Accurate mediastinal nodal staging directs therapy, and provides prognostic value during the management of Non-Small Cell Lung Cancer (NSCLC).

The Assessment of Surgical Staging vs Endosonographic Ultrasound in Lung Cancer (ASTER) trial compared an endosonographic staging strategy with surgical staging using mediastinoscopy. Endosonography combines endobronchial, and transesophageal ultrasound, and is followed up using mediastinoscopy, in case the results are negative.

The researchers evaluated 241 patients suffering from potentially resectable NSCLC, in 4 tertiary referral centers. There were 123 patients randomized to endosonographic staging, and 118 patients to surgical staging. The researchers found that endosonography was significantly more sensitive (97%) during the diagnosis of mediastinal nodal metastases, compared to surgical staging (79%).

The five-year survival rate was 35% for both the endosonographic and surgical strategies. The estimated median survival for the endosonographic strategy was 31 months compared to 33 months for the surgical strategy. The researchers concluded that improved mediastinal staging could ensure better treatment for a larger number of patients, and could increase the long-term survival rates of the patients.

Jouke T. Annema, MD, PhD, Academic Medical Center, Amsterdam (Amsterdam, Netherlands), said, "Why did improved mediastinal staging not lead to improved survival? Missing data occurred in less than 2 percent and therefore are an unlikely source of bias. However, ASTER was powered to detect a difference in diagnostic sensitivity, not survival, as reflected by the wide confidence intervals. If a survival difference between the strategies exists, it is likely to be small and a larger sample size may be needed to detect it. However, randomized trials to detect a survival difference based on staging strategy are not likely to be conducted as the endosonographic strategy is now advised in clinical guidelines."

Related Links:
Academic Medical Center


Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Syringe Pump
SP50 Series
Radiofrequency Generator
GX1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Graphical Abstract (Aoibhin M. Sheedy et al., A replenishable peritoneal implant for localized delivery and peritoneal fluid sampling in ovarian cancer, Device (2026). DOI: 10.1016/j.device.2026.101050)

New Implant Provides Sustained Localized Therapy for Ovarian Cancer

Ovarian cancer is often diagnosed at advanced stages because symptoms such as bloating, pain, and pelvic pressure are nonspecific. Standard care relies on surgery and systemic therapy, yet tools for targeted... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.